Market Place
Sourcing Support
BioSenic reports half year 2024 results
30 Sep 2024 //
GLOBENEWSWIRE
BioSenic Begins Searching For New Assets & Board Changes
30 Sep 2024 //
GLOBENEWSWIRE
BioSenic S.A. : Transparency notification received from Mr François Rieger
19 Jul 2024 //
GLOBENEWSWIRE
BioSenic Analyzes Phase 2 Data For Arsenic Trioxide In CGVHD Trial
18 Jul 2024 //
GLOBENEWSWIRE
BioSenic S.A. : Transparency notification received from Véronique Pomi
12 Jul 2024 //
GLOBENEWSWIRE
Medsenic, subsidiary of BioSenic SA, extends key patent to the United States
05 Jul 2024 //
GLOBENEWSWIRE
Medsenic Signs New Licensing Agreements With Phebra PTY Ltd
02 Jul 2024 //
GLOBENEWSWIRE
BioSenic S.A. : Information on the total number of voting rights and shares
28 Jun 2024 //
GLOBENEWSWIRE
BioSenic New Subscription Agreement EUR 2.1M Convertible Bonds
21 Jun 2024 //
GLOBENEWSWIRE
Court Approves BioSenic Restructuring Plan
13 Jun 2024 //
GLOBENEWSWIRE
BioSenic to host Annual General Meeting on July 12, 2024
12 Jun 2024 //
GLOBENEWSWIRE
BioSenic announces 2023 full year results
06 Jun 2024 //
GLOBENEWSWIRE
BioSenic S.A. : Information on the total number of voting rights and shares
30 May 2024 //
GLOBENEWSWIRE
Biosenic Restructuring Plan Approved: Creditor Vote In Favor 2024-2032
27 May 2024 //
GLOBENEWSWIRE
BioSenic provides First Quarter 2024 Business Update
24 May 2024 //
GLOBENEWSWIRE
BioSenic S.A. : Information on the total number of voting rights and shares
30 Apr 2024 //
GLOBENEWSWIRE
BioSenic Publishes Restructuring Plan for Nivelles Court
26 Apr 2024 //
GLOBENEWSWIRE
BioSenic Postpones AGM, Provides 2023 Unaudited Financials
24 Apr 2024 //
GLOBENEWSWIRE
BioSenic S.A. : Transparency notifications received from Fran§ois Rieger
18 Apr 2024 //
GLOBENEWSWIRE
BioSenic Provides Restructuring Plan Details
12 Apr 2024 //
GLOBENEWSWIRE
BioSenic Submits 2024-2030 Restructuring Plan To Nivelles Court
11 Apr 2024 //
GLOBENEWSWIRE
BioSenic S.A. : Information on the total number of voting rights and shares
29 Mar 2024 //
GLOBENEWSWIRE
BioSenic presents successful preclinical data on its ATO medication
20 Mar 2024 //
GLOBENEWSWIRE
BioSenic releases details of optimized administration approach
12 Mar 2024 //
GLOBENEWSWIRE
BioSenic S.A. : Information on the total number of voting rights and shares
29 Feb 2024 //
GLOBENEWSWIRE
BioSenic raises ‚¬500,000 in private placement of new shares
02 Feb 2024 //
GLOBENEWSWIRE
BioSenic provides support to European conference on graft-versus-host disease
31 Jan 2024 //
GLOBENEWSWIRE
BioSenic patent granted in Canada for protection of ATO therapeutic platform
30 Jan 2024 //
GLOBENEWSWIRE
BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd.
15 Jan 2024 //
GLOBENEWSWIRE
BioSenic S.A. : Transparency notifications received from Fran§ois Rieger
15 Jan 2024 //
GLOBENEWSWIRE
BioSenic appoints Dr Carole Nicco as Chief Operating Officer
10 Jan 2024 //
GLOBENEWSWIRE
BioSenic signs a new subscription agreement for a maximum of EUR 1.2M
08 Jan 2024 //
GLOBENEWSWIRE
BioSenic on its way to find funds to perform trial on Graft-versus-Host Disease
08 Dec 2023 //
GLOBENEWSWIRE
BioSenic on its way to find funds to perform trial on Graft-versus-Host Disease
06 Dec 2023 //
GLOBENEWSWIRE
BioSenic provides third quarter 2023 Business Update
25 Oct 2023 //
GLOBENEWSWIRE
BioSenic to draw the final tranches of its Tech Opportunities 15 bonds program
18 Oct 2023 //
GLOBENEWSWIRE
BioSenic S.A. : Transparency notifications received from François Rieger
17 Oct 2023 //
GLOBENEWSWIRE
BioSenic S.A. : Information on the total number of voting rights and shares
05 Oct 2023 //
GLOBENEWSWIRE
BioSenic performs further analysis of its phase 2 clinical trial data
27 Sep 2023 //
GLOBENEWSWIRE
BioSenic publishes evidence of beneficial effects of arsenic trioxide treatment
19 Sep 2023 //
GLOBENEWSWIRE
BioSenic reaches agreement on binding term sheets with main creditors
13 Sep 2023 //
GLOBENEWSWIRE
BioSenic reports half year 2023 results
07 Sep 2023 //
GLOBENEWSWIRE
BioSenic S.A. : Information on the total number of voting rights and shares
01 Sep 2023 //
GLOBENEWSWIRE
BioSenic receives a Chinese patent, protecting combined use of metal ions and arsenic salts
24 Aug 2023 //
GLOBENEWSWIRE
BioSenic S.A. : Information on the total number of voting rights and shares
03 Aug 2023 //
GLOBENEWSWIRE
BioSenic provides further update on negotiations with its main creditors
07 Jul 2023 //
GLOBENEWSWIRE
BioSenic S.A. : Information on the total number of voting rights and shares
03 Jul 2023 //
GLOBENEWSWIRE
BioSenic provides financial update
30 Jun 2023 //
GLOBENEWSWIRE
BioSenic presents data on its new copper-arsenic trioxide combination
20 Jun 2023 //
GLOBENEWSWIRE
BioSenic puts Phase IIb ALLOB trial on hold
19 Jun 2023 //
GLOBENEWSWIRE
BioSenic SA : Information on the total number of voting rights and shares
01 Jun 2023 //
GLOBENEWSWIRE
BioSenic provides update regarding current license agreement with Phebra
29 May 2023 //
GLOBENEWSWIRE
BioSenic & Pluristyx sign term sheet for market availability of ALLOB
24 May 2023 //
GLOBENEWSWIRE
BioSenic provides First Quarter 2023 Business Update
22 May 2023 //
GLOBENEWSWIRE
BioSenic to host Annual General Meeting on June 14 2023
15 May 2023 //
GLOBENEWSWIRE
BioSenic announces 2022 full year results
27 Apr 2023 //
GLOBENEWSWIRE
BioSenic receives key European patent from EPO, for further therapeutic
18 Apr 2023 //
GLOBENEWSWIRE
BioSenic appoints Lieven Huysse, MD, as Chief Medical Officer
03 Apr 2023 //
GLOBENEWSWIRE
BioSenic provides Financial Update and Financial Calendar 2023
31 Mar 2023 //
GLOBENEWSWIRE
BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)
30 Mar 2023 //
GLOBENEWSWIRE
